58
Participants
Start Date
August 18, 2023
Primary Completion Date
January 10, 2026
Study Completion Date
March 10, 2026
RH5.1 and/or RH5.2-VLP with Matrix-M
"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The RH5.2 protein consists of the stabilised core region of PfRH5 antigen with SpyTag fused at the C-terminus. The RH5.2-SpyTag protein is conjugated to hepatitis B surface antigen (HBsAg)-SpyCatcher to produce the final RH5.2-VLP vaccine.~The Matrix-M has been developed and manufactured by Novavax AB and is presented as a liquid solution in a glass vial."
Centre for Clinical Vaccinology & Tropical Medicine (CCVTM), Oxford
University of Oxford
OTHER